Pancreatic adverse events in patients treated with immune checkpoint inhibitors

Pancreatic adverse events in patients treated with immune checkpoint inhibitors

Abstract Background and Aim The inhibition of cytotoxic T‐lymphocyte associated antigen‐4 (CTLA‐4) and programmed cell death‐1 (PD‐1) has been a target for multiple drugs to enhance the T‐cell antitumor activity. However, these immune checkpoint inhibitors (ICIs) come with a panel of immune‐related...

Full description

Bibliographic Details
Main Authors: Caroline Hana, Tauseef Rehman, Kyeeun Park, Carlos Carracedo Uribe, Pyi Phyo Aung, Brian Hunis, Matthew Salzberg, Jennifer Zikria, Atif Hussein
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:JGH Open
Subjects:
diabetic ketoacidosis
immune checkpoint inhibitors
immune‐related adverse events
pancreatitis
Online Access:https://doi.org/10.1002/jgh3.12875

Internet

https://doi.org/10.1002/jgh3.12875

Similar Items